Obtaining valid laboratory data in clinical trials conducted in resource diverse settings: lessons learned from a Microbicide Phase III Clinical Trial

T Crucitti, K Fransen, R Maharaj, T Tenywa, M Massinga Loembe, KG Murugavel, K Mendonca, S Abdellati, G Beelaert, L Van Damme

    Research output: Contribution to journalA1: Web of Science-article

    Abstract

    BACKGROUND: Over the last decade several phase III microbicides trials have been conducted in developing countries. However, laboratories in resource constrained settings do not always have the experience, infrastructure, and the capacity to deliver laboratory data meeting the high standards of clinical trials. This paper describes the design and outcomes of a laboratory quality assurance program which was implemented during a phase III clinical trial evaluating the efficacy of the candidate microbicide Cellulose Sulfate 6% (CS) [1]. METHODOLOGY: In order to assess the effectiveness of CS for HIV and STI prevention, a phase III clinical trial was conducted in 5 sites: 3 in Africa and 2 in India. The trial sponsor identified an International Central Reference Laboratory (ICRL), responsible for the design and management of a quality assurance program, which would guarantee the reliability of laboratory data. The ICRL provided advice on the tests, assessed local laboratories, organized trainings, conducted supervision visits, performed re-tests, and prepared control panels. Local laboratories were provided with control panels for HIV rapid tests and Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) amplification technique. Aliquots from respective control panels were tested by local laboratories and were compared with results obtained at the ICRL. RESULTS: Overall, good results were observed. However, discordances between the ICRL and site laboratories were identified for HIV and CT/NG results. One particular site experienced difficulties with HIV rapid testing shortly after study initiation. At all sites, DNA contamination was identified as a cause of invalid CT/NG results. Both problems were timely detected and solved. Through immediate feedback, guidance and repeated training of laboratory staff, additional inaccuracies were prevented. CONCLUSIONS: Quality control guidelines when applied in field laboratories ensured the reliability and validity of final study data. It is essential that sponsors provide adequate resources for implementation of such comprehensive technical assessment and monitoring systems. TRIAL REGISTRATION: ClinicalTrials.gov NCT00153777 and Current Controlled Trials ISRCTN95638385
    Original languageEnglish
    JournalPLoS ONE
    Volume5
    Issue number10
    Pages (from-to)e13592
    ISSN1932-6203
    DOIs
    Publication statusPublished - 2010

    Keywords

    • B780-tropical-medicine
    • Viral diseases
    • HIV
    • AIDS
    • Sexually transmitted diseases
    • STD
    • Gonorrhea
    • Neisseria gonorrhoeae
    • Chlamydia trachomatis
    • Prevention
    • Women
    • Microbicides
    • Clinical trials
    • Data collection
    • Data processing
    • Quality assurance
    • Effectiveness
    • Reliability
    • Validation
    • Local
    • Decentralization
    • Laboratory diagnosis
    • Africa-General
    • India
    • Asia-South
    • Belgium
    • Europe-West

    Fingerprint Dive into the research topics of 'Obtaining valid laboratory data in clinical trials conducted in resource diverse settings: lessons learned from a Microbicide Phase III Clinical Trial'. Together they form a unique fingerprint.

    Cite this